The MIRAGE trial is the only randomized trial to date comparing these state-of-the-art technologies in radiation oncology. It ...

AMPLIFY-7P Phase 2 randomized study anticipated to complete enrollment in Q4 2024; formal interim analysis of disease-free survival (“DFS”) expected in H1 2025 Poster presentation at the Society ...

News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...

NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based ...

New results from a pooled analysis of patients will be featured in a late-breaking presentation at the upcoming European ...

The largest ever clinical trial of T cell therapy for solid tumors has ended, heralding a new era for precision T cell ...

Data from the pivotal Phase 2b ReNeu trial demonstrate that patients with NF1-PN achieved deep responses and improvements in ...

The largest ever clinical trial of T cell therapy (a type of cell-based immunotherapy) for solid tumours has been completed. Led by a Singapore clinician-investigator, the global, international, ...

Goldman Sachs upgrades BioNTech to Buy, highlighting the potential of its cancer drug BNT327 and forecasting strong future ...

Panelist discusses how the second interim overall survival data from MARIPOSA-2, presented at the European Society for ...

Evidence suggests that combining metformin with standard of care could increase survival and offer other benefits to patients with high-volume disease.

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious ...